Marzena O.
- Country
- Poland
- Department
- Klinika i Poliklinika Układowych Chorób Tkanki Łącznej
Research Overview
- Long-Term Safety and Tolerability Assessment of Dapirolizumab Pegol in Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Extension Study
- Efficacy and Safety Evaluation of Nipocalimab in Adults with Active Idiopathic Inflammatory Myopathies: A Phase 2, Randomized, Double-blind, Placebo-controlled Study
- Efficacy and Safety Evaluation of Subcutaneous Sibeprenlimab in Sjögren’s Disease: A Phase 2 Randomized, Double-blind, Placebo-controlled Trial
Data & Insights
Has run more than one trial at 29 of 121 partner sites.
Specializations
Connective Tissue and Systemic Autoimmune Diseases
Marzena Olesinska is involved in clinical research across a broad range of systemic autoimmune diseases, with particular emphasis on systemic lupus erythematosus, systemic sclerosis, and Sjögren’s disease. Her research landscape also includes lupus nephritis, cutaneous lupus erythematosus, and related multisystem inflammatory conditions.
- Systemic lupus erythematosus
- Systemic sclerosis
- Sjögren’s disease
- Lupus nephritis
- Cutaneous lupus erythematosus
Her activity in this area extends to systemic inflammatory manifestations and organ involvement, reflecting a strong therapeutic focus on autoimmune disease control.
Inflammatory Arthritis and Spondyloarthritis
Her clinical trial involvement includes multiple forms of inflammatory arthritis, especially rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis. The portfolio also covers juvenile and refractory rheumatic disease states.
- Rheumatoid arthritis
- Psoriatic arthritis
- Axial spondyloarthritis
- Ankylosing spondylitis
- Juvenile idiopathic arthritis
This area includes interest in axial symptoms, disease activity control, and treatment options for persistent or difficult-to-manage inflammatory joint disease.
Idiopathic Inflammatory Myopathies and Vasculitis
Marzena Olesinska is also active in research on idiopathic inflammatory myopathies, including dermatomyositis and polymyositis, as well as immune-mediated necrotizing myopathy. Her clinical scope further includes ANCA-associated vasculitis and related systemic immune-mediated disorders.
- Idiopathic inflammatory myopathies
- Dermatomyositis
- Polymyositis
- Immune-mediated necrotizing myopathy
- ANCA-associated vasculitis
Her therapeutic interest in this field centers on severe inflammatory muscle and vascular disease, where targeted immunomodulation remains a major area of medical innovation.
Skin, Allergy, and Immune-Mediated Inflammatory Conditions
Her research profile includes psoriasis, chronic spontaneous urticaria, bullous pemphigoid, and other immune-mediated dermatologic disorders. It also extends to inflammatory conditions with mucocutaneous or systemic overlap, such as Behçet’s syndrome and SAPHO syndrome.
- Psoriasis
- Chronic spontaneous urticaria
- Bullous pemphigoid
- Behçet’s syndrome
- SAPHO syndrome
This domain reflects a therapeutic focus on immune-driven skin disease and associated inflammatory syndromes requiring advanced biologic strategies.
Cardiometabolic and Supportive Therapeutic Areas
Her trial portfolio also reaches beyond rheumatology into cardiovascular disease, heart failure with preserved ejection fraction, atrial fibrillation, type 2 diabetes, and obesity. Additional interest is seen in supportive and symptom-focused conditions such as sarcopenia, chronic pain, and post-surgical neuropathic pain.
- Cardiovascular disease
- Heart failure with preserved ejection fraction
- Atrial fibrillation
- Type 2 diabetes
- Chronic pain
These areas indicate involvement in therapeutic research addressing cardiometabolic risk, functional decline, and pain-related impairment alongside immune-mediated disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.